CD137 antibody | 4B4-1
Filter by Application:F Reset
|Mouse anti Human CD137, clone 4B4-1 recognizes CD137. CD137 (also known as 4-1BB ligand receptor or TNFRSF9) is a type I transmembrane glycoprotein of the Tumor Necrosis Factor receptor family that is expressed on activated T and NK cells, dendritic cells, myeloid cells and at the surface of some non-lymphoid cells under specific conditions (Schwarz et al. 1995). CD137 acts as a receptor for 4-1BB ligand, expressed on activated macrophages, activated B cells, hematopoietic stem cells and myeloid progenitor cells (Pollock et al. 1994) and for some proteins of the extracellular matrix (Chalupny et al. 1992).
The interaction between CD137 and 4-1BBL acts as a co-stimulatory signal for the activation, expansion and survival of T cells (Wen et al. 2002). CD137 signaling is involved in the generation of CD8+ T cells and enhance their cytotoxic activity (Shuford et al. 1997). Because of its ability to promote the anti-tumorigenic activity of cytotoxic T cells, CD137 is the target of several cancer immune therapies, such as the agonist anti-CD137 Urelumab (Segal et al. 2017) and Utomilumab (Chester et al. 2018).
CD137 also binds to the adaptor proteins TRAF1, 2 and 3 to promote NF-kappaB activation (Jang et al. 1998).
Mouse anti-human CD137, clone 4B4-1 has been reported to immunoprecipitate a homodimeric protein of 32kDa under reducing conditions and 85kDa under non-reducing conditions (Garni-Wagner et al. 1996).
- Target Species
- Species Cross-Reactivity
Target Species Cross Reactivity Primate
- N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- <0.1% Sodium Azide (NaN3)
- Recombinant human CD137 ectodomain
- >95% by SDS PAGE
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- For research purposes only
- Guaranteed for 12 months from the date of despatch or until the date of expiry, whichever comes first. Please see label for expiry date.
This product should be stored undiluted.
|Application Name||Verified||Min Dilution||Max Dilution|
References for CD137 antibody
Schwarz, H. et al. (1995) ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages.
Blood. 85 (4): 1043-52.
Pollok, K.E. et al. (1994) 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells.
Eur J Immunol. 24 (2): 367-74.
Chalupny, N.J. et al. (1992) T-cell activation molecule 4-1BB binds to extracellular matrix proteins.
Proc Natl Acad Sci U S A. 89 (21): 10360-4.
Wen, T. et al. (2002) 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.
J Immunol. 168 (10): 4897-906.
Shuford, W.W. et al. (1997) 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.
J Exp Med. 186 (1): 47-55.
Segal, N.H. et al. (2017) Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
Clin Cancer Res. 23 (8): 1929-1936.
Chester, C. et al. (2018) Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
Blood. 131 (1): 49-57.
Jang, I.K. et al. (1998) Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B.
Biochem Biophys Res Commun. 242 (3): 613-20.
View The Latest Product References
Garni-wagner, B.A. et al. (1996) 4-1BB is expressed on CD45RAhiROhi transitional T cell in humans.
Cell Immunol. 169 (1): 91-8.
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.Yes, sign me up